Savara Inc. (NASDAQ:SVRA) Q4 2019 Earnings Conference Call - Final Transcript
Mar 12, 2020 • 04:30 pm ET
The impact as you heard earlier on the AVAIL study, especially in patients living with cystic fibrosis, travel is going to be an issue. So the exact impact is unknown. And this is why we're going to -- we made the decision to close the enrollment for that study at the end of Q2 versus waiting until we get to 150.
But we are monitoring the situation and implementing whatever practices are needed to protect safety of our employees, our business operations, as well as our patients. I think that's it. Thank you, everybody. We will always be here for conferences with investors, should it be needed. Thank you. Bye-bye.
[Operator Closing Remarks]